Mono-3-hydroxybutyl phthalate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Mono-3-hydroxybutyl phthalate
• 英文别名: 2-(3-hydroxybutoxycarbonyl)benzoic acid
• 化学式: C₁₂H₁₄O₅
• 分子量: 238.24
• InChiKey: CTDCWBUTXCPHAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Laxative preparation containing l-Arginine
  申请人：Norgine BV

  公开号：EP2022494A2

  公开（公告）日：2009-02-11

  The invention relates to L-arginine, a derivative thereof or a pharmaceutically acceptable salt thereof for use as a laxative, for treatment of constipation and for clearing the rectum and/or the colon of a mammal. Compositions suitable for topical administration to an area of the gastrointestinal tract are provided. Orally administered preparations comprising for example an enteric coating that dissolves at a desired location in the gastrointestinal tract; a controlled release formulation; a sustained release formulation; a targeted drug delivery system; or a combination thereof are also provided.

  本发明涉及用作泻药、治疗便秘和清除哺乳动物直肠和/或结肠的 L-精氨酸、其衍生物或其药学上可接受的盐。提供了适用于胃肠道局部给药的制剂。此外，还提供了口服制剂，例如包括可在胃肠道所需位置溶解的肠溶衣；控释制剂；缓释制剂；靶向给药系统；或其组合。
• [EN] DEGRADABLE BIO-BASED MASTERBATCH AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF,<br/>[FR] BIOMÉLANGE MAÎTRE DÉGRADABLE, PROCÉDÉ POUR SA PRÉPARATION ET UTILISATION CORRESPONDANTE<br/>[ZH] 一种可降解生物基母粒及其制备方法与应用
  申请人：KINGFA SCIENCE & TECHNOLOGY CO

  公开号：WO2020134850A1

  公开（公告）日：2020-07-02

  一种可降解生物基母粒及其制备方法与应用，属于高分子材料改性领域。所述可降解生物基母粒包括生物降解聚酯和生物填料，所述生物降解聚酯的熔融指数为8-80g/10min，所述生物降解聚酯的熔融指数是根据ASTM D1238使用2.16kg重量并在190℃的温度测量；所述生物填料来自于天然的生物质资源，所述生物填料的粒径D 50为0.5～8μm；所述生物降解聚酯和生物填料的重量比为20-40：60-80；所述可降解生物基母粒中，占总碳重量60％-100％的碳来源于生物基的碳。以生物填料为原料制得了可降解生物基母粒，同时，以该可降解生物基母粒为原料制得了生物可降解聚酯组合物，该生物可降解聚酯组合物生物可降解性好且具有优异的机械性质。
• LAXATIVE PREPARATION CONTAINING L-ARGININE
  申请人：Norgine Research Limited

  公开号：EP1251844A2

  公开（公告）日：2002-10-30
• Laxative preparation
  申请人：Barras Norman

  公开号：US20050080137A1

  公开（公告）日：2005-04-14

  The invention relates to L-arginine, a derivative thereof or a pharmaceutically acceptable salt thereof for use as a laxative, for treatment of constipation and for clearing the rectum and/or the colon of a mammal. Compositions suitable for topical administration to an area of the gastrointestinal tract are provided. Orally administered preparations comprising for example an enteric coating that dissolves at a desired location in the gastrointestinal tract; a controlled release formulation; a sustained release formulation; a targeted drug delivery system; or a combination thereof are also provided.
• LONG DELAYED RELEASE LAXATIVE
  申请人：EMPIRE TECHNOLOGY DEVELOPMENT LLC

  公开号：US20160151296A1

  公开（公告）日：2016-06-02

  Disclosed herein are compositions and methods for treating or preventing the build-up or entrapment of fecal matter in the colon. The compositions and methods disclose a delayed release laxative that provides for the release of the laxative if colon-specific conditions are achieved, otherwise the laxative passes out of the body. The condition specific release of laxatives prevents harmful side effects from excessive use of non-delayed release laxatives.